EU drug regulator finds no link between weight-loss drugs and suicidal thoughts

The review focused on medicines that contain either liraglutide or semaglutide, the active ingredient in Wegovy. File picture

The European Union drug regulator has found no evidence, following a nine-month probe, that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts.

The regulator's Pharmacovigilance Risk Assessment Committee, which monitors drugs' side-effects, said that no updates were required to the treatments' product information after reviewing the available evidence.